PDF(Pubmed)
Abstract：
UNASSIGNED: Combining transarterial chemoembolization (TACE) with systemic therapy has shown significant efficacy for intermediate-stage hepatocellular carcinoma (HCC) patients. This study aimed to validate the therapeutic efficacy of TACE combined with atezolizumab and bevacizumab (TACE + Atez/Bev) compared to TACE alone.
UNASSIGNED: A retrospective study was conducted across three centers in China, encompassing 155 patients at the intermediate-stage of HCC. Propensity Score Matching (PSM) was used to minimize selection bias, with a ratio of 1:1. Primary outcomes were TACE-specific Progression-Free Survival (PFS) and Overall Survival (OS). Objective Response Rate (ORR) and Disease Control Rate (DCR) were assessed based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Adverse events (AEs) related to treatment were analyzed to evaluate safety.
UNASSIGNED: Before PSM, the TACE + Atez/Bev group demonstrated extended median OS (not reached vs 20.3 months, P = 0.004) and PFS (20.0 months vs 9.8 months, P = 0.029) compared to the TACE-alone group. The TACE + Atez/Bev group also had a higher ORR (60.9% vs 41.3%, P = 0.026) and DCR (89.1% vs 58.7%, P < 0.001) than the TACE-alone group. After applying the PSM, the study included 42 pairs of patients. Compared to the TACE-alone group, the combination therapy group also showed significantly longer median OS (not reached vs 21.4 months, P = 0.008) and PFS (21.7 vs 9.7 months, P = 0.009). The combination therapy group also had a higher ORR (66.7% vs 38.1%, P = 0.009) and DCR (92.9% vs 57.1%, P < 0.001). AEs in the combination therapy group were mostly manageable, with the most common being elevated liver transaminase.
UNASSIGNED: In treating intermediate-stage HCC, the survival benefit of combining TACE with atezolizumab and bevacizumab was significantly higher than TACE alone, and the treatment was well-tolerated.
UNASSIGNED: A retrospective study was conducted across three centers in China, encompassing 155 patients at the intermediate-stage of HCC. Propensity Score Matching (PSM) was used to minimize selection bias, with a ratio of 1:1. Primary outcomes were TACE-specific Progression-Free Survival (PFS) and Overall Survival (OS). Objective Response Rate (ORR) and Disease Control Rate (DCR) were assessed based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Adverse events (AEs) related to treatment were analyzed to evaluate safety.
UNASSIGNED: Before PSM, the TACE + Atez/Bev group demonstrated extended median OS (not reached vs 20.3 months, P = 0.004) and PFS (20.0 months vs 9.8 months, P = 0.029) compared to the TACE-alone group. The TACE + Atez/Bev group also had a higher ORR (60.9% vs 41.3%, P = 0.026) and DCR (89.1% vs 58.7%, P < 0.001) than the TACE-alone group. After applying the PSM, the study included 42 pairs of patients. Compared to the TACE-alone group, the combination therapy group also showed significantly longer median OS (not reached vs 21.4 months, P = 0.008) and PFS (21.7 vs 9.7 months, P = 0.009). The combination therapy group also had a higher ORR (66.7% vs 38.1%, P = 0.009) and DCR (92.9% vs 57.1%, P < 0.001). AEs in the combination therapy group were mostly manageable, with the most common being elevated liver transaminase.
UNASSIGNED: In treating intermediate-stage HCC, the survival benefit of combining TACE with atezolizumab and bevacizumab was significantly higher than TACE alone, and the treatment was well-tolerated.
摘要：
■经动脉化疗栓塞（TACE）与全身治疗相结合对中期肝细胞癌（HCC）患者具有显着疗效。本研究旨在验证TACE联合阿特珠单抗和贝伐单抗（TACE+Atez/Bev）与单独TACE相比的疗效。
■在中国的三个中心进行了一项回顾性研究，涵盖155例肝癌中期患者。倾向得分匹配(PSM)用于最小化选择偏差，比例为1:1。主要结果是TACE特异性无进展生存期（PFS）和总生存期（OS）。根据改良的实体瘤反应评估标准（mRECIST）评估客观反应率（ORR）和疾病控制率（DCR）。分析与治疗相关的不良事件(AE),评价其安全性。
■PSM之前，TACE+Atez/Bev组表现出延长的中位OS（未达到20.3个月，P=0.004）和PFS（20.0个月vs9.8个月，P=0.029）与TACE单独组相比。TACE+Atez/Bev组的ORR也较高（60.9%对41.3%，P=0.026）和DCR（89.1%对58.7%，P<0.001）比TACE单独组。应用PSM后，该研究包括42对患者。与单独使用TACE组相比，联合治疗组也显示出显著更长的中位OS(未达到vs21.4个月，P=0.008）和PFS（21.7vs9.7个月，P=0.009)。联合治疗组的ORR也较高(66.7%vs38.1%,P=0.009)和DCR(92.9%vs57.1%，P<0.001)。联合治疗组的AE大多是可控的，最常见的是肝脏转氨酶升高。
■在治疗中期肝癌时，TACE联合阿特珠单抗和贝伐单抗的生存获益显著高于单独TACE,治疗耐受性良好。
■在中国的三个中心进行了一项回顾性研究，涵盖155例肝癌中期患者。倾向得分匹配(PSM)用于最小化选择偏差，比例为1:1。主要结果是TACE特异性无进展生存期（PFS）和总生存期（OS）。根据改良的实体瘤反应评估标准（mRECIST）评估客观反应率（ORR）和疾病控制率（DCR）。分析与治疗相关的不良事件(AE),评价其安全性。
■PSM之前，TACE+Atez/Bev组表现出延长的中位OS（未达到20.3个月，P=0.004）和PFS（20.0个月vs9.8个月，P=0.029）与TACE单独组相比。TACE+Atez/Bev组的ORR也较高（60.9%对41.3%，P=0.026）和DCR（89.1%对58.7%，P<0.001）比TACE单独组。应用PSM后，该研究包括42对患者。与单独使用TACE组相比，联合治疗组也显示出显著更长的中位OS(未达到vs21.4个月，P=0.008）和PFS（21.7vs9.7个月，P=0.009)。联合治疗组的ORR也较高(66.7%vs38.1%,P=0.009)和DCR(92.9%vs57.1%，P<0.001)。联合治疗组的AE大多是可控的，最常见的是肝脏转氨酶升高。
■在治疗中期肝癌时，TACE联合阿特珠单抗和贝伐单抗的生存获益显著高于单独TACE,治疗耐受性良好。
